Advertisement
Phase 2 trial of zerlasiran yields first demonstration of longer effect with each dose of an siRNA
Undetectable levels achieved for nearly nine months in phase 1 trial
Targeted mRNA blocking could be first effective approach specific to this cardiovascular risk factor
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Advertisement